The Cardiac Arrhythmia Program is among the most active arrythmia research centers in the world. See a selection of currently active arrhythmia clinical trials.

NIH-Sponsored Trials

CABANA–Catheter Ablation vs. Anti–Arrhythmic Drug Therapy for A–Fib

A multi-center, randomized trial to compare the effect of percutaneous catheter ablation versus current state–of–the–art drug therapy on total mortality among patients with atrial fibrillation. Other important endpoints: stroke, quality of life and healthcare costs.

PI: Francis E. Marchlinski, MD

ARVC Registry

ARVC-NIH sponsored registry of patients with suspected or diagnosed arrhythmogenic right ventricular cardiomyopathy (ARVC) focusing on the genetics, mechanisms and clinical phenotypes during long term follow up.

PI: Francis E. Marchlinski, MD

Atrial fibrillation ablation trials

TactiCath PAS

A multi-center post approval study to assess the safety and efficacy of the contact force sensing catheter during atrial fibrillation ablation.

PI: Francis E. Marchlinski, MD

Zero AF

A randomized multi-center trial to assess safety and efficacy of the Blazer open-irrigated ablation catheter for use during atrial fibrillation ablation.

PI: Gregory Supple, MD

Smart-SF (pending)

A prospective safety assessment of a contact force sensing catheter during atrial fibrillation ablation.

Oral Anticoagulation Therapy Pilot Study

A multi-center randomized trial to determine the safety of withdrawing oral anticoagulation in patients with high risk for thromboembolism following successful atrial fibrillation ablation.

PI: Michael Riley, MD PhD

Ventricular tachycardia (VT) ablation trials

STAR VT

A multi-center, randomized study of VT ablation vs conventional medical therapy in patients with spontaneous or inducible VT (high risk for recurrent episodes) undergoing ICD or CRT-D implant to assess for clinical outcome (reduction in number of ICD shocks for VT).

PI: David Frankel, MD

Pacemaker/implantable defibrillator trials

Adapt Response Study

A prospective randomized multi-center post market Cardiac Resynchronization Therapy (CRT) in heart failure trial.

PI: David Frankel, MD

Share This Page: